Franklin Resources Inc. Lowers Position in Amgen Inc. $AMGN

Franklin Resources Inc. lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 11.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 2,642,072 shares of the medical research company’s stock after selling 352,045 shares during the period. Franklin Resources Inc. owned 0.49% of Amgen worth $745,562,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock valued at $15,204,047,000 after buying an additional 165,281 shares in the last quarter. State Street Corp grew its stake in shares of Amgen by 0.6% during the 2nd quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock valued at $8,196,775,000 after acquiring an additional 177,035 shares during the period. Capital International Investors increased its holdings in Amgen by 1.5% in the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after acquiring an additional 282,219 shares in the last quarter. Capital World Investors raised its stake in Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after acquiring an additional 1,935,876 shares during the period. Finally, Geode Capital Management LLC raised its stake in Amgen by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock worth $3,619,489,000 after acquiring an additional 291,271 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on AMGN. Barclays assumed coverage on shares of Amgen in a research report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target for the company. Leerink Partners restated a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. Citigroup lifted their target price on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Erste Group Bank raised shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Finally, Mizuho increased their price target on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $354.00.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Prominent market commentator Josh Brown argued that large-cap biotech names are resilient to disruption, which supports investor appetite for Amgen as a stable growth biotech. Josh Brown: Biotech growth stocks immune to disruption risk
• Positive Sentiment: Analysis highlighting Amgen’s oncology advances and a resilient dividend argues the company’s product progress and cash generation underpin long‑term growth, a supportive signal for income and growth investors. Amgen Oncology Advances Test Dividend Strength And Long Term Growth Story
• Neutral Sentiment: Seeking Alpha published the transcript of Amgen’s presentation at the Leerink Global Healthcare Conference — useful for pipeline, management commentary and strategic color, but no single market-moving announcement in the transcript. Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: A valuation piece assesses whether AMGN shares are mispriced after mixed returns — useful background for longer‑term positioning but not an immediate catalyst. Assessing Whether Amgen (AMGN) Shares Look Mispriced After Recent Mixed Returns
• Neutral Sentiment: Short‑interest reports in the feed show anomalous/zero values and contradictory entries for March — current data appears unreliable and is not a usable signal for positioning right now.
• Negative Sentiment: Jefferies initiated coverage on Amgen with a Hold and set a $350 price target, below the current market price — this analyst call introduces near‑term downside pressure and may weigh on sentiment. Jefferies initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: New federal legislation (H.R. 7871) that would formalize value‑based purchasing in Medicaid and change price/rebate calculations could create pricing/reporting pressures for manufacturers, introducing regulatory risk for Amgen’s marketed drugs. New Bill: Representative Brett Guthrie introduces H.R. 7871: Medicaid VBPs for Patients Act

Amgen Price Performance

Shares of Amgen stock opened at $377.64 on Thursday. The firm has a market cap of $203.57 billion, a PE ratio of 26.54, a PEG ratio of 3.72 and a beta of 0.45. The stock has a 50 day moving average of $356.15 and a 200 day moving average of $324.33. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. Amgen’s dividend payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.